Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors

Quality of Life Research

Volumn 15, Issue 5, 2006, Pages 791-800

  Oldenburg, Jan ^a,b,c   Fosså, Sophie D ^a,b   Dahl, Alv A ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Cisplatin; Neurotoxicity; Ototoxicity; Patient based rating; Rating; Scale

Indexed keywords

CISPLATIN;

ADULT; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NEUROTOXICITY; CORRELATION COEFFICIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RAYNAUD PHENOMENON; RELIABILITY; SAMPLING; SELF REPORT; SENSORY NEUROPATHY; SIDE EFFECT; TESTIS CANCER; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; NORWAY; PSYCHOMETRICS; QUESTIONNAIRES; SURVIVAL; TESTICULAR NEOPLASMS;

EID: 33744487652     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-005-5370-6     Document Type: Article

References (33)

1. LH Einhorn 1981 Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture Cancer Res 41 9 Pt 1 3275 3280
2. LH Einhorn 2002 Curing metastatic testicular cancer Proc Natl Acad Sci USA 99 7 4592 4595
3. SD Fossa 2004 Long-term sequelae after cancer therapy - survivorship after treatment for testicular cancer Acta Oncol 43 2 134 141
4. C Bokemeyer CC Berger MA Kuczyk HJ Schmoll 1996 Evaluation of long-term toxicity after chemotherapy for testicular cancer J Clin Oncol 14 11 2923 2932
5. A Kedar ME Cohen AI Freeman 1978 Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: A case report Cancer Treat Rep 62 5 819 821
6. D Screnci MJ [tmp] McKeage P Galettis TW Hambley BD Palmer BC Baguley 2000 Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs Br J Cancer 82 4 966 972
7. L Troy K [tmp] McFarland S Littman-Power 2000 Cisplatin-based therapy: A neurological and neuropsychological review Psychooncology 9 1 29 39
8. MK Tuxen SW Hansen 1994 Neurotoxicity secondary to antineoplastic drugs Cancer Treat Rev 20 2 191 214
9. RJ Cersosimo 1989 Cisplatin neurotoxicity Cancer Treat Rev 16 4 195 211
10. M von Schlippe CJ Fowler SJ Harland 2001 Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: Time course and prognosis Br J Cancer 85 6 823 826
11. SD Fossa R de Wit JT Roberts 2003 Quality of life in good prognosis patients with metastatic germ cell cancer: A prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20) J Clin Oncol 21 6 1107 1118
12. ES [tmp] McDonald KR Randon A Knight AJ Windebank 2005 Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity Neurobiol Dis 18 2 305 313
13. I Barajon M Bersani M Quartu 1996 Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy Exp Neurol 138 1 93 104
14. MW van Ruijven JC de Groot GF Smoorenburg 2004 Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study Hear Res 197 1-2 44 54
15. C Bokemeyer CC Berger JT Hartmann 1998 Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer Br J Cancer 77 8 1355 1362
16. JA Block W Sequeira 2001 Raynaud's phenomenon Lancet 357 9273 2042 2048
17. D Adoue P Arlet 1984 Bleomycin and Raynaud's phenomenon Ann Intern Med 100 5 770
18. M Boyer D Raghavan 1992 Toxicity of treatment of germ-cell tumors Semin Oncol 19 2 128 142
19. K Kanno Y Hirata T Emori 1991 Endothelin and Raynaud Phenomenon Am J Med 90 1 130 132
20. FN Brand MG Larson WB Kannel JM [tmp] McGuirk 1997 The occurrence of Raynaud's phenomenon in a general population: The Framingham Study Vasc Med 2 4 296 301
21. KT Palmer MJ Griffin H Syddall B Pannett C Cooper D Coggon 2000 Prevalence of Raynaud's phenomenon in Great Britain and its relation to hand transmitted vibration: A national postal survey Occup Environ Med 57 7 448 452
22. N Ahmad M Seidman 2004 Tinnitus in the older adult: Epidemiology, pathophysiology and treatment options Drugs Aging 21 5 297 305
23. SD Fossa C Moynihan S Serbouti 1996 Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study Support Care Cancer 4 2 118 128
24. R de Wit JT Roberts PM Wilkinson 2001 Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J Clin Oncol 19 6 1629 1640
25. DH Moore J Donnelly WP [tmp] McGuire 2003 Limited access trial using amifostine for protection against cisplatin- and 3-hour paclitaxel-induced neurotoxicity: A phase II study of the Gynecologic Oncology Group J Clin Oncol 21 22 4207 4213
26. EA Calhoun EE Welshman CH Chang 2003 Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy Int J Gynecol Cancer 13 6 741 748
27. SD Fossa AA Dahl JH Loge 2003 Fatigue, anxiety, and depression in long-term survivors of testicular cancer J Clin Oncol 21 7 1249 1254
28. RD Mosteller 1987 Simplified calculation of body-surface area N Engl J Med 317 17 1098
29. AA Dahl A Mykletun SD Fossa 2005 Qualtiy of life in survivors of testicular cancer Urol Oncol 23 3 193 200
30. B Engdahl K Tambs HM Borchgrevink HJ Hoffman 2005 Screened and unscreened hearing threshold levels for the adult population: Results from the Nord-Trondelag hearing loss study Int J Audiol 44 4 213 230
31. J. Rust S Golombok 1999 Modern Psychometrics 2 Routledge London and New York
32. D Cella A Peterman S Hudgens K Webster MA Socinski 2003 Measuring the side effects of taxane therapy in oncology: The functional assesment of cancer therapy-taxane (FACT-taxane) Cancer 98 4 822 831
33. HR Maricq PH Carpentier MC Weinrich 1993 Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs. Tarentaise, Savoie, France J Rheumatol 20 1 70 76